Arcus Launches Underwritten Stock Offering Days After Strong Casdatifan Data
RCUS sits 16% above its 52-week low of $16.41 on elevated volume (2.8× avg).
Summary
Arcus kicked off an underwritten public offering of common stock, with all shares sold by the company and a 30-day option for underwriters to buy up to 15% more. No size or price was disclosed, so the dilution overhang is unknown for now. The timing is notable: shares ran up after the Oct 20 ARC-20 casdatifan data (14.5-month median PFS, 77% 18-month survival), and the company just pre-announced roughly $694M in cash and securities as of Sept 30. Issuing equity into that strength suggests management wants capital while the stock is elevated. Jefferies, Leerink and TD Cowen are running the books. Pricing terms will set the real signal — a deep discount to the $19 level would hit harder than the headline dilution itself.
At the time of this announcement, RCUS was trading at $19.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $16.41 to $31.74. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.